Preclinical Study Presented at the International Congress of Endocrinology Shows Intravail Drug Delivery Technology Provides Unmatched Non-Invasive Delivery of an Anti-Obesity Peptide

SAN DIEGO, Nov. 12, 2008/MarketWire/  Aegis Therapeutics LLC announced today that preclinical data was presented at the 2008 International Congress of Endocrinology in Rio de Janeiro, Brasil  demonstrating that its Intravail® formulation technology provides unmatched non-invasive delivery of the OB-3 peptide, a peptide previously shown to control weight gain and glucose levels in an animal model of diabetes. 

The results of the study, presented by Dr. Patricia Grasso, Associate Professor in the Department of Medicine and Center for Cell Biology and Cancer Research, Albany Medical College, Albany NY, examined the uptake profile, serum half-life, and relative bioavailability of [D-Leu-4] OB3 in male Swiss Webster mice comparing peptide delivery by the intranasal and three separate injection routes. Intranasal delivery using the homogeneous aqueous Intravail® excipient formulation provided higher bioavailability than that achieved using intraperitoneal, subcutaneous, or intramuscular injection.

The authors concluded that intranasal delivery of this peptide may have potential as a novel, convenient, and non-invasive approach to the treatment of obesity and its associated metabolic dysfunctions in humans.  

The complete citation of this study is: “Uptake Of Mouse [D-Leu-4] OB3, A Synthetic Peptide Amide With Leptin-Like Activity, In Male Swiss Webster Mice; A Pharmacokinetic Study Comparing Intraperitoneal, Subcutaneous, Intramuscular, And Intranasal Delivery Systems.” Author(s): Novakovic ZM; Leinung MC; Lee DW; Grasso P; ICE 2008 - International Congress of Endocrinology Nov. 08-12, 2008 - Rio de Janeiro – Brasil (Abstract No. 00198).

About Aegis Therapeutics

Aegis Therapeutics LLC is a drug delivery technology company commercializing its patented or proprietary drug delivery and drug formulation technologies through product-specific licenses. Our Intravail® drug delivery technology enables the non-invasive delivery of a broad range of protein, peptide and non-peptide macromolecular therapeutics that can currently only be administered by injection. Aegis’ Intravail® absorption enhancement agents provide exceptionally high and unmatched bioavailability performance, comparable in efficiency to subcutaneous injection, via the intranasal administration route.  Intravail® has also been successfully applied to buccal, oral, and rectal administration of both small molecule and peptidic drugs.  Our ProTek® technology allows creation of proprietary, easily manufacturable, and stable aqueous or lyophilized dosage forms that maintain the integrity and physiological activity of many protein and peptide therapeutics. ProTek® technology is applicable to injectable, intranasal, and other dosage forms of peptide or protein therapeutics. 

 

For more information about Aegis, please visit the Aegis website: http://www.aegisthera.com.

 
 

Contact: Ralph Barry, Chief Business Officer

Aegis Therapeutics LLC

1-858-618-1400 Ext. 102

Email: rbarry@aegisthera.com

 
 
 


 

 

Posted: November 2008

View comments

Hide
(web5)